MorphoSys

Aadi Bioscience Announces Planned Leadership Transition

Retrieved on: 
星期二, 十一月 8, 2022
Constellation, Triple-negative breast cancer, MBA, NASDAQ, COO, KRAS, NYU, TSC2, Pomalidomide, Growth, FDA, Company, TSC1, Private Securities Litigation Reform Act, CCO, NSCLC, Gilead Sciences, Sacituzumab govitecan, Immunomedics, CEO, MorphoSys, Protein-bound paclitaxel, New York University Stern School of Business, Business, AADI, Celgene, Forward-looking statement, Hematology, Lenalidomide, Leadership, Rutgers University, Biology, Marketing, Perivascular epithelioid cell tumour, BS, Risk, Cancer, Time, Management, Pharmaceutical industry, Security (finance), Aadi, Genentech

"I have had the opportunity to work with Brendan since he joined Aadi as Chief Operating Officer in September 2021.

Key Points: 
  • "I have had the opportunity to work with Brendan since he joined Aadi as Chief Operating Officer in September 2021.
  • Since that time his expertise and leadership have been instrumental in building the organization in preparation for the growth that lies ahead," saidNeil Desai, Ph.D., Founder, President and Chief Executive Officer ofAadi Bioscience.
  • Going forward, Brendan will assume leadership of the Company as we continue to gain momentum on all of these fronts.
  • Dr. Desai is the founder of Aadi Bioscience and has served as its President and CEO since 2011.

Xencor Reports Third Quarter 2022 Financial Results

Retrieved on: 
星期一, 十一月 7, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, AES, Atopic dermatitis, Society, Company, GSK, Immunotherapy, Income, Private Securities Litigation Reform Act, Degenerative disease, MCRPC, U.S. Securities and Exchange Commission, Vir, Autoimmune disease, Annual report, AE, Janssen, Monoclonal antibody, CD3, Investor, Antibody, NK, Biotechnology, Follicular lymphoma, G&A, Hematology, SITC, Forward-looking statement, COVID-19, Psoriasis, Genentech, Protein engineering, Biology, Form 10-K, Cytokine, Annual general meeting, Lenalidomide, NASDAQ, Novartis, IgG4-related disease, Lymphoma, CD25, Research, R, Sale, Safety, Technology, Review, PARP, CD20, Patient, Cancer, DLBCL, Prostate cancer, Hoffmann-La Roche, Investment, Marketing, Therapy, CD28, Security (finance), Vaccine, Pharmaceutical industry, Renewable energy, Life insurance, Regulatory T cell, MorphoSys, Alexion, Astellas Pharma

XmAb564 (IL2-Fc): Today, Xencor announced initial results from its single-dose Phase 1a study of XmAb564, administered subcutaneously in healthy volunteers.

Key Points: 
  • XmAb564 (IL2-Fc): Today, Xencor announced initial results from its single-dose Phase 1a study of XmAb564, administered subcutaneously in healthy volunteers.
  • Vir Biotechnology, Inc.: In the third quarter of 2022, Xencor reported $17.8 million in royalty revenue under the Companys agreement with Vir.
  • Financial Results for the Third Quarter Ended September 30, 2022
    Cash, cash equivalents, receivables and marketable debt securities totaled $654.6 million as of September 30, 2022, compared to $664.1 million on December 31, 2021.
  • ET (1:30 p.m. PT) to discuss the third quarter 2022 financial results, provide a corporate update and present results from the Phase 1a study of XmAb564.

EQS-News: MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting

Retrieved on: 
星期一, 十一月 7, 2022
Constellation, FC, Cyclophosphamide, Adult, Bruise, CD19, Flushing, PFS, Dor, ADCC, Fever, Rituximab, Partnership, CD20, RCHOP, Sheraton New Orleans, ADCP, Food, CST, Final Analysis, ASCT, ASH, Rash, BET, Safety, Lenalidomide, Chills, Blinded, Prednisone, TD, JAK, Gene, Cancer, Pharmacokinetics, PET, ORR, Progression-free survival, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ruxolitinib, Headache, Lymphoid leukemia, Immunotherapy, Arm, Vincristine, Incyte, Apoptosis, Death, Bleeding, Doxorubicin, GLA, Pharmaceutical industry, Medical imaging, Vaccine, Patient, DLBCL, Infection, Tafasitamab, MorphoSys, Primary myelofibrosis

As a global commercial-stage biopharmaceutical company, we use groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients.

Key Points: 
  • As a global commercial-stage biopharmaceutical company, we use groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients.
  • Pelabresib is being investigated as a treatment for myelofibrosis and has not yet been evaluated or approved by any regulatory authorities.
  • MANIFEST (NCT02158858) is an open-label Phase 2 clinical trial of pelabresib in patients with myelofibrosis.
  • Serious infections, including infections that can cause death, have happened in people during treatments with MONJUVI and after the last dose.

EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors

Retrieved on: 
星期五, 十月 28, 2022
Peripheral T-cell lymphoma, U.S. Securities and Exchange Commission, American Association for Cancer Research, Clinical trial, EZH2, Medical director, LinkedIn, Hair, NASDAQ, Primary peritoneal carcinoma, Neutropenia, National Cancer Institute, BAP1, Treatment, Mesothelioma, Patient, ARID1A, Thrombocytopenia, Anemia, Neoplasm, Fatigue, Research, Communication, Annual report, EORTC, Judgement, National, Diarrhea, Industry, Nausea, EZH1, American Association, Risk, Lymphoma, AES, AACR, Twitter, Therapy, European Organisation for Research and Treatment of Cancer, Joint Planning and Development Office, Dysgeusia, Oncology nursing, Half-life, FSE, Vomiting, NCI, Learning, Pharmaceutical industry, Cancer, MorphoSys

Advanced cancer patients who have progressed following prior therapies have significant treatment needs that might benefit from a targeted approach with an EZH2 inhibitor.

Key Points: 
  • Advanced cancer patients who have progressed following prior therapies have significant treatment needs that might benefit from a targeted approach with an EZH2 inhibitor.
  • At trial entry, 68% of patients had been treated with at least three prior lines of therapy.
  • Of the 10 evaluable patients with ovarian clear cell carcinoma, four had a partial response and three had stable disease.
  • These initial results support patient selection based on ARID1A and BAP1 in the ongoing Phase 2 expansion study.

EQS-News: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis  

Retrieved on: 
星期五, 十月 28, 2022
Janus, U.S. Securities and Exchange Commission, American College, Clinical trial, LinkedIn, Rheumatoid arthritis, Contrast, NASDAQ, Safety, Cancer, IIL, ACR20, Disease-modifying antirheumatic drug, Janus kinase inhibitor, GSK, III, Communication, Program, Annual report, Patient, Judgement, Industry, RA, Risk, Twitter, Health, American College of Rheumatology, Population, FSE, Pharmaceutical industry, MorphoSys

MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner, GSK plc (LSE/NYSE: GSK), provided an update on the ContRAst phase III program for otilimab as apotential treatment of moderate to severe rheumatoid arthritis (RA).

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner, GSK plc (LSE/NYSE: GSK), provided an update on the ContRAst phase III program for otilimab as apotential treatment of moderate to severe rheumatoid arthritis (RA).
  • The ContRAst phase IIl program enrolled a broad range of difficult-to-treat patients who had an inadequate response to or could not tolerate available treatments.
  • GSK is planning to submit full results from the ContRAst phase III program for publication in 2023.
  • As a global commercial-stage biopharmaceutical company, we use groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients.

EQS-News: MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022

Retrieved on: 
星期六, 十月 22, 2022
LinkedIn, U.S. Securities and Exchange Commission, Communication, Lenalidomide, ADCP, Annual report, Regulation of tobacco by the U.S. Food and Drug Administration, Tafasitamab, Incyte, Patient, Income, Twitter, Judgement, SG, Cancer, Food, DLBCL, Industry, FC, Immunotherapy, Adult, CD19, ADCC, Clinical trial, ASCT, Lymphoid leukemia, Apoptosis, Risk, Health insurance, Vaccine, Pharmaceutical industry, MorphoSys

53% to 58% of mid-point of SG&A expenses represent Monjuvi U.S. selling costs of which 100% are recorded in MorphoSys income statement.

Key Points: 
  • 53% to 58% of mid-point of SG&A expenses represent Monjuvi U.S. selling costs of which 100% are recorded in MorphoSys income statement.
  • At MorphoSys, we are driven by our mission: More life for people with cancer.
  • As a global commercial-stage biopharmaceutical company, we use groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients.
  • MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts.

Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil

Retrieved on: 
星期四, 十月 6, 2022
ANVISA, GUD, Tafasitamab, Lenalidomide, Therapy, MorphoSys, TSX, ADCP, Annual report, Regulation of tobacco by the U.S. Food and Drug Administration, NASDAQ, Patient, Knight Therapeutics, Food, DLBCL, FC, Nature, Adult, Immunotherapy, Intention, GLOBE, ADCC, United Kingdom, Laboratorio de Energía Solar Termoeléctrica, ASCT, Lymphoid leukemia, Apoptosis, Pharmaceutical industry, Vaccine, Security (finance), Knight, Incyte, Uniting Medically Supervised Injecting Centre

We are delighted to reach this key milestone for tafasitamab in Brazil, said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics.

Key Points: 
  • We are delighted to reach this key milestone for tafasitamab in Brazil, said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics.
  • Upon approval, combination therapy with tafasitamab and lenalidomide will be an important new therapeutic option for eligible patients with relapsed or refractory DLBCL in Brazil.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
  • Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2021 as filed on www.sedar.com .

LifeMine Therapeutics Expands Management Team with Appointments of Martin Stahl, Ph.D., as Chief Scientific Officer and Louis Plamondon, Ph.D., as Executive Vice President and Head of CMC

Retrieved on: 
星期四, 十月 6, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Constellation, Philippe Ciais, Gemstone, Doctor of Philosophy, Therapy, Computer, Head, Cambridge Crystallographic Data Centre, ChemMedChem, Cell engineering, Multiple myeloma, Bortezomib, Patient, Pharmacy, CMC, Computational chemistry, Drug discovery, Multiplicity of infection, Negotiation, Harvard University, Journal, University of Freiburg, Medicinal chemistry, University, Biophysics, Journal of Medicinal Chemistry, Data science, Biochemistry, Fine chemical, Pharmaceutical industry, MorphoSys, Chemistry

LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced the appointments of Martin Stahl, Ph.D., as chief scientific officer and Louis Plamondon, Ph.D., as executive vice president and head of CMC.

Key Points: 
  • LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced the appointments of Martin Stahl, Ph.D., as chief scientific officer and Louis Plamondon, Ph.D., as executive vice president and head of CMC.
  • Dr. Stahl, former global head of lead discovery at Roche, will also lead LifeMines operations at its European offices in Basel, Switzerland.
  • Martin and Louis are stellar additions to the LifeMine executive team and share in our vision to reinvent small molecule drug discovery through genomic search and retrieval from the biosphere, said Gregory Verdine, Ph.D., co-founder, president and chief executive officer of LifeMine.
  • Martin and Louis experience and expertise will only help further accelerate our efforts.

EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL

Retrieved on: 
星期三, 九月 28, 2022
Adult, Apoptosis, Rash, Headache, ASCT, Infection, The Year's Best Science Fiction: Tenth Annual Collection, Lenalidomide, Incidence, Twitter, Bleeding, Food, FSE, ADCC, Diarrhea, Chills, Flushing, LinkedIn, Joint Planning and Development Office, SOHO, MorphoSys, FC, Immunotherapy, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Cancer, Lymphoid leukemia, B-cell lymphoma, CD19, Hematology-Oncology and Stem Cell Transplantation Research Center, Tafasitamab, Incyte, Bruise, ADCP, NASDAQ, Polyclinic, Fever, Society, Death, DLBCL, Medical imaging, Pharmaceutical industry, Vaccine, Neutropenia

At data cutoff (February 15, 2022), 27 of 80 patients (34%) had undergone treatment for at least 2 years, with a median duration of treatment of 4.3 years.

Key Points: 
  • At data cutoff (February 15, 2022), 27 of 80 patients (34%) had undergone treatment for at least 2 years, with a median duration of treatment of 4.3 years.
  • Of those 27, 23 patients were alive at data cutoff, and 13 remained on treatment, including six who were on treatment for at least 5 years.
  • A complete response was observed in 23 of the 27 patients, including four who were refractory to their primary therapy.
  • A partial response was seen in four patients, two of whom were still on treatment at data cutoff.

MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL

Retrieved on: 
星期三, 九月 28, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Adult, Apoptosis, Rash, Headache, ASCT, Infection, The Year's Best Science Fiction: Tenth Annual Collection, Lenalidomide, Incidence, Twitter, Bleeding, Food, ADCC, FSE, Diarrhea, Chills, Flushing, LinkedIn, Joint Planning and Development Office, SOHO, FC, Immunotherapy, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Cancer, Lymphoid leukemia, B-cell lymphoma, CD19, Hematology-Oncology and Stem Cell Transplantation Research Center, Tafasitamab, Incyte, Bruise, ADCP, NASDAQ, Polyclinic, Fever, Oncology, Society, Death, DLBCL, Pharmaceutical industry, Medical imaging, Vaccine, Neutropenia, MorphoSys

At data cutoff (February 15, 2022), 27 of 80 patients (34%) had undergone treatment for at least 2 years, with a median duration of treatment of 4.3 years.

Key Points: 
  • At data cutoff (February 15, 2022), 27 of 80 patients (34%) had undergone treatment for at least 2 years, with a median duration of treatment of 4.3 years.
  • Of those 27, 23 patients were alive at data cutoff, and 13 remained on treatment, including six who were on treatment for at least 5 years.
  • A complete response was observed in 23 of the 27 patients, including four who were refractory to their primary therapy.
  • A partial response was seen in four patients, two of whom were still on treatment at data cutoff.